ArticleThe Journal of infectious diseases2020
Trachoma Prevalence After Discontinuation of Mass Azithromycin Distribution.
Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Community-level trachoma ecological associations and the use of geospatial analysis methods: A systematic review.PLoS neglected tropical diseases · 2022Pooled it
- Stopping azithromycin mass drug administration for trachoma: A systematic review.PLoS neglected tropical diseases · 2021Pooled it
- Dynamics of trachoma infection in West Africa revealed by a hidden state model.PLoS computational biology · 2026Article
- Monitoring of Chlamydia trachomatis infection and antibodies in low-prevalence districts of Amhara, Ethiopia: Insights from a hyper-endemic trachoma region.PLoS neglected tropical diseases · 2026Article
- Assessing trachoma elimination progress in districts with persistent trachoma, Western Province, Zambia.International health · 2025Article
- Wait and watch: A trachoma surveillance strategy from Amhara region, Ethiopia.PLoS neglected tropical diseases · 2024Article
- Forecasting the elimination of active trachoma: An empirical model.PLoS neglected tropical diseases · 2022Article
- What Can Modeling Tell Us About Sustainable End Points for Neglected Tropical Diseases?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Modelling trachoma post-2020: opportunities for mitigating the impact of COVID-19 and accelerating progress towards elimination.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021Article
- When, Who, and How to Sample: Designing Practical Surveillance for 7 Neglected Tropical Diseases as We Approach Elimination.The Journal of infectious diseases · 2020Article
- Insights from mathematical modelling and quantitative analysis on the proposed 2030 goals for trachoma.Gates open research · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
Abstract
backgroundAs the World Health Organization seeks to eliminate trachoma by 2020, countries are beginning to control the transmission of trachomatous inflammation-follicular (TF) and discontinue mass drug administration (MDA) with oral azithromycin. We evaluated the effect of MDA discontinuation on TF1-9 prevalence at the district level.
methodsWe extracted from the available data districts with an impact survey at the end of their program cycle that initiated discontinuation of MDA (TF1-9 prevalence <5%), followed by a surveillance survey conducted to determine whether TF1-9 prevalence remained below the 5% threshold, warranting discontinuation of MDA. Two independent analyses were performed, 1 regression based and 1 simulation based, that assessed the change in TF1-9 from the impact survey to the surveillance survey.
resultsOf the 220 districts included, TF1-9 prevalence increased to >5% from impact to surveillance survey in 9% of districts. Regression analysis indicated that impact survey TF1-9 prevalence was a significant predictor of surveillance survey TF1-9 prevalence. The proportion of simulations with >5% TF1-9 prevalence in the surveillance survey was 2%, assuming the survey was conducted 4 years after MDA.
conclusionAn increase in TF1-9 prevalence may represent disease resurgence but could also be due to measurement error. Improved diagnostic tests are crucial to elimination of TF1-9 as a public health problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.